phase 2a

Related by string. Phase 2a * phases . Phases . PHASE : Phase III clinical trials . Phase III trials . Phase III clinical / 2As . 2AS : Class 2A Sectional . Evergreen 2A * initiate Phase 2a . Phase 2a clinical . Phase 2a trial . Phase 2a proof . Phase 2a clinical trials . Phase 2a Clinical Trial . Phase 2a Trial . Phase 2a randomized . Phase 2a IBS . Phase 2a Study . Phase 2a preventative *

Related by context. All words. (Click for frequent words.) 79 Phase 2a 78 phase IIa 77 Phase 2a clinical 76 phase IIb 76 Phase 1b 75 Phase IIa 75 Phase IIa clinical 75 Phase Ib 75 phase IIa clinical 75 Phase Ib clinical 75 Phase 2b study 74 Phase 1b clinical 74 Phase IIa trial 74 Phase IIb clinical 74 phase IIb clinical 73 Phase 1a clinical 73 Phase 2b 73 Phase Ib study 73 phase Ib 73 Phase 2a trial 73 dose escalation Phase 72 Phase IIb 72 Phase 2b clinical 72 Phase III 72 phase IIb study 71 Phase 1b trial 71 randomized Phase IIb 71 multicenter Phase 71 Phase III clinical 71 multicenter Phase II 71 Phase Ib II 71 Phase #/#a 71 Phase II 70 Phase 1a 70 Phase IIb trial 70 alvespimycin 70 phase IIb trial 70 placebo controlled clinical 70 Phase #b/#a 70 Phase IIB 70 Phase Ia 70 pivotal Phase III 69 Phase IIb trials 69 Phase 2b clinical trials 69 placebo controlled Phase 69 BRIM3 69 ongoing Phase 1b 69 APEX PD 69 Phase IIb clinical trials 69 dose escalation trial 68 dose escalation clinical 68 ADVANCE PD 68 INCB# [001] 68 ELACYT 68 Phase IIIb clinical 68 BRIM2 68 randomized controlled Phase 68 oral ridaforolimus 68 HuMax EGFr 68 GALNS 68 confirmatory Phase III 68 oral rivaroxaban 68 phase Ib clinical 68 Phase IIa trials 68 VNP#M 67 pharmacokinetic PK study 67 Phase III placebo controlled 67 Phase 2b trial 67 riociguat 67 forodesine 67 multiple ascending dose 67 Phase 2a clinical trials 67 CRLX# 67 multicenter randomized Phase 67 registrational trial 67 pharmacokinetic PK 67 dose escalation study 67 Phase III pivotal 66 multicenter randomized placebo controlled 66 randomized Phase III 66 preclinical efficacy 66 pharmacokinetics PK 66 Phase IIb III 66 ganetespib 66 pivotal Phase 66 Cloretazine ® 66 Phase #b/#a clinical 66 Phase 1b clinical trials 66 IIa trial 66 velafermin 66 MEND CABG 66 rALLy clinical trial 66 ToGA 66 SUCCEED trial 66 cannabinor 66 initiate Phase 1b 66 PFO migraine 66 pharmacokinetic studies 66 teriflunomide 66 Phase IIIb 66 CUSTOM III 66 NO# [002] 66 registrational 66 elotuzumab 65 PDE4 inhibitor 65 multicenter placebo controlled 65 RSD# oral 65 mertansine 65 Phase Ib IIa 65 Aplidin 65 Archexin 65 Phase #b/#a trial 65 KRN# 65 QLT# 65 Cloretazine R VNP#M 65 Corlux 65 selective androgen receptor modulator 65 MAGE A3 ASCI 65 HGS ETR1 65 randomized Phase 2b 65 NVA# 65 EOquin TM 65 midstage trials 65 oral prodrug 65 pharmacodynamic PD 65 phase IIb III 65 ABSORB trial 65 blinded randomized placebo controlled 65 rNAPc2 65 lintuzumab 65 pivotal bioequivalence 65 Phase III clinical trials 65 ruxolitinib 65 huC# DM4 65 confirmatory Phase 3 65 phase IIIb 65 reslizumab 65 pertuzumab 65 ISIS # 65 TASKi2 65 Phase Ib clinical trials 65 axitinib 65 SPIRIT FIRST 65 Phase III confirmatory 65 Phase III ALLEGRO 65 Synavive 65 assessing T DM1 65 viral kinetic 65 randomized Phase 65 NP2 Enkephalin 65 Phase III randomized controlled 65 Initiated Phase 64 Tarceva TM 64 tanespimycin 64 JAK inhibitor 64 trodusquemine 64 trastuzumab emtansine T DM1 64 virus HCV protease inhibitor 64 elacytarabine 64 LymphoStat B TM 64 neratinib 64 aclidinium bromide 64 CLIRS 64 multicenter Phase III 64 Zybrestat 64 dosing cohort 64 bicifadine 64 TOLAMBA 64 GLP toxicology studies 64 placebo controlled Phase III 64 Cloretazine 64 confirmatory clinical 64 huN# DM1 64 TPI ASM8 64 ATL# [001] 64 compound INCB# 64 PXD# 64 Factor VIIa 64 GOUT 64 Xanafide 64 lomitapide 64 Capesaris 64 Amrubicin 64 deforolimus 64 R#/MEM # 64 Phase IIa clinical trials 64 Sym# 64 Alzhemed TM 64 Arikace 64 dose cohort 64 GAMMAGARD 64 initiated Phase Ib 64 PRX # 64 vidofludimus 64 OncoVEX GM CSF 64 PROSTVAC TM 64 dose dose escalation 64 varespladib 64 denufosol 64 initiate Phase IIb 64 Allovectin 7 64 histone deacetylase HDAC inhibitor 64 DASISION 64 EVEREST II 63 glufosfamide 63 Phase III trials 63 fosbretabulin 63 SinuNase TM 63 GRN# 63 OvaRex ® MAb 63 Dacogen injection 63 eniluracil 63 enzastaurin 63 dose cohorts 63 MERLIN TIMI 63 HGS ETR2 63 Fx #A 63 IMA# 63 dirucotide 63 placebo controlled 63 Phase IIa proof 63 Phase 2b kidney transplant 63 acyclovir Lauriad R 63 vascular disrupting agent 63 PD LID 63 Phase III psoriasis 63 Phase 2b monotherapy 63 ocular formulation 63 crizotinib PF # 63 ACAPODENE 63 fidaxomicin Phase 3 63 ENDEAVOR III 63 PERSEUS 63 Phase IIA 63 Prestara 63 INCB# [002] 63 BrachySil 63 Traficet EN 63 clinical trial 63 Exherin TM 63 LCP Tacro 63 ZD# [001] 63 double blinded placebo 63 HGS# 63 double blinded randomized 63 EXPAREL ™ 63 trastuzumab DM1 T DM1 63 Glufosfamide 63 evaluating tivozanib 63 unblinding 63 HuMax CD4 63 Mipomersen 63 tezampanel 63 stated Michelle Berrey 63 dosing cohorts 63 QNEXA 63 multicenter clinical 63 TRO# 63 laquinimod 63 efficacy endpoint 63 NGX# 63 Annamycin 63 CR# vcMMAE 63 romidepsin 63 TBC# 63 Phase lll 63 Onrigin 63 liposomal formulation 63 LUX Lung 63 UPLYSO 63 TACI Ig 63 Randomized Phase 63 Bezielle 63 single ascending dose 63 Bicifadine 63 Phase 1b dose escalation 63 PHX# 63 tramiprosate Alzhemed TM 63 IIa clinical trial 63 dyskinesia PD LID 63 CAMMS# 63 RhuDex 63 Tocosol Paclitaxel 63 ProSavin 63 AZILECT R 63 PRT# 63 cathepsin K inhibitor 63 dexanabinol 63 prospective multicenter randomized 63 obatoclax 62 randomized multicenter 62 AEGR 62 PreCISe 62 PF # [002] 62 AeroLEF TM 62 Tanespimycin 62 ascending dose 62 eltrombopag 62 Pimavanserin 62 PDX pralatrexate 62 TMC# [002] 62 receptor tyrosine kinase inhibitor 62 TMC# C# 62 initiate Phase 2b 62 CIMZIA TM certolizumab pegol 62 CBLC# 62 Hsp# Inhibitor 62 YONDELIS 62 Genz # 62 incyclinide 62 RSR# 62 FOLOTYN ® 62 OncoVEX 62 brivaracetam 62 ALKS 62 IIa trials 62 HCV RESPOND 2 62 alemtuzumab Campath 62 multicentre randomized 62 pomalidomide 62 Tesetaxel 62 ocrelizumab 62 DDP# 62 RSD# 62 ponatinib 62 VESTASYNC 62 AMD# [002] 62 Ophena TM 62 Ostarine 62 treatment naive genotype 62 metastatic castration resistant 62 multicenter phase 62 sorafenib Nexavar 62 APTIVUS 62 Alocrest 62 hepatitis B vaccine Heplisav 62 PANVAC VF 62 Carfilzomib 62 Phenoptin 62 lintuzumab SGN 62 LymphoStat B belimumab 62 AP# [003] 62 PEG PAL 62 including eniluracil ADH 62 treatment naïve genotype 62 IMPACT IMmunotherapy 62 talactoferrin 62 celgosivir 62 PrevOnco 62 dose escalation phase 62 vosaroxin 62 Plicera 62 satraplatin Phase 62 placebo controlled randomized 62 Urocidin 62 ORAL Sync 62 tolevamer 62 Oglemilast 62 belinostat 62 Initiate Phase 62 PS# [001] 62 IDX# 62 lumiliximab 62 entinostat 62 CLORETAZINE TM VNP#M 62 Prostate AdenoCarcinoma Treatment 62 GLYX 62 non nucleoside inhibitor 62 diabetic neuropathic pain 62 XL# SAR# 62 DermaVir Patch 62 ORENCIA ® 62 solithromycin 62 midstage clinical 62 ILLUMINATE 62 inhaled AAT 62 sNDA submission 62 multicenter randomized double 62 cediranib 62 mGluR5 negative 62 CTAP# Capsules 62 Phase III randomized 62 Quinamed 62 Pharmacokinetics PK 62 ANCHOR trial 62 PSMA ADC 62 STRIDE PD 62 Ocrelizumab 62 Aurexis 62 midstage clinical trials 62 allosteric modulator NAM 62 GetGoal Phase III 62 Safinamide 62 sitaxsentan 62 ThGRF 62 CEQ# 62 PSN# [002] 62 torezolid phosphate 62 davunetide intranasal AL 62 prucalopride 62 ZYBRESTAT 62 LibiGel Phase III 62 CRMD# 62 randomized controlled multicenter 62 Vernakalant 62 Tyrima 61 iniparib 61 beta 1a 61 LibiGel ® 61 Phase 2b randomized 61 TEMSO 61 BAY #-# 61 neurogenic orthostatic hypotension 61 Phase III ADT 61 interferon gamma 1b 61 LCP AtorFen 61 FTY# fingolimod 61 Serada 61 sapacitabine 61 Laquinimod 61 OncoVex 61 ProLindac 61 alvimopan 61 BETAS 61 ularitide 61 multicenter randomized controlled 61 IIb clinical trial 61 seliciclib CYC# 61 baminercept 61 CHAMPION PCI 61 AIR CF1 61 galiximab 61 PREOS 61 orally bioavailable 61 Orazol 61 PRIMO CABG 61 Zenvia ™ 61 Targretin capsules 61 Phase #/#a trial 61 urocortin 2 61 Elagolix 61 Civacir 61 Zenvia Phase III 61 randomized placebo controlled 61 HCV SPRINT 61 tesmilifene 61 Azedra 61 DCCR 61 EndoTAG TM -1 61 IRX 2 61 Pivotal Phase III 61 Troxatyl 61 Aclidinium 61 dose escalation 61 PRECiSE 61 Vitaxin 61 R# #mg BID 61 Androxal TM 61 administered subcutaneously 61 prospective randomized multicenter 61 BCX# 61 radiation sensitizer 61 pharmacokinetic 61 randomized multicenter trial 61 trial evaluating PRX# 61 Azixa 61 fostamatinib 61 Denufosol 61 Zoraxel 61 trastuzumab DM1 61 PI3K/Akt pathway inhibitor 61 AVOREN 61 BrachySil TM 61 ataluren 61 Gattex 61 AEG# 61 subcutaneous PRO 61 GRN#L 61 Phase III Pivotal 61 initiate Phase Ib 61 ASA# 61 lorvotuzumab mertansine 61 RhuDex TM 61 Virulizin ® 61 AVADO 61 OncoGel 61 LBH# 61 perifosine KRX 61 Phase IIIb study 61 SYMMETRY trial 61 albiglutide 61 Nasdaq MAPP 61 Aflibercept 61 ascending doses 61 ara C 61 OXi# 61 Dapagliflozin 61 RhuDex ® 61 EGS# 61 relapsed refractory multiple myeloma 61 Ceflatonin 61 adecatumumab MT# 61 budesonide foam 61 COMFORT II 61 Ozarelix 61 Tarvacin TM 61 CIMZIA TM 61 XmAb# 61 NASDAQ CLDX 61 mapatumumab 61 Zemplar Capsules 61 Personalized Immunotherapy 61 ThermoDox R 61 LEVADEX ™ 61 oral deforolimus 61 Phase IIb Trial 61 Pirfenidone 61 TG MV 61 relapsed MM 61 Combination REOLYSIN R 61 Benlysta belimumab 61 generation purine nucleoside 61 sunitinib malate 61 nucleotide analog 61 bardoxolone 61 dextromethorphan quinidine 61 PNP inhibitor 61 demonstrated antitumor activity 61 AQ4N 61 MEK inhibitor RDEA# 61 MAP# 61 Fentanyl TAIFUN R 61 trabedersen 61 Relovair 61 GLP1 agonist 61 oral FTY# 61 metastatic hormone refractory 61 Panzem R NCD 61 Cinquil 61 PRIMO CABG2 61 investigational humanized monoclonal antibody 61 preclinical pharmacokinetic 61 randomized controlled 61 CIP TRAMADOL ER 61 Ophena 61 investigational protease inhibitor 61 TOCOSOL Paclitaxel 61 controlled multicenter 61 SNT MC# 61 Darusentan 61 safety tolerability pharmacokinetic 61 Desmoteplase 61 ENDEAVOR IV clinical 61 ZFP Therapeutic 61 arzoxifene 61 multicenter randomized 60 Panzem R 60 BIBW 60 ACTEMRA TM 60 Spiegelmer ® 60 CDP# 60 Apoptone 60 aclidinium 60 generation PNP inhibitor 60 registrational Phase 60 amrubicin 60 Locteron ® 60 oral treprostinil 60 BCIRG 60 PEG SN# 60 ORMD 60 Microplasmin 60 Pegasys plus Copegus 60 Viramidine 60 EVIZON 60 IMPACT DCM 60 GLPG# 60 omacetaxine mepesuccinate 60 polymerase inhibitor 60 thorough QT 60 oral Xeloda 60 afamelanotide 60 EFAPROXYN 60 BLOOM DM 60 photoprotective drug 60 eprotirome 60 Azedra TM 60 controlled multicenter Phase 60 oral salmon calcitonin 60 double blind placebo 60 Atu# 60 SinuNase ™ 60 pradefovir 60 rilonacept 60 OvaRex R 60 IMGN# 60 metaglidasen 60 Guanilib 60 Phase III multicenter 60 Naproxcinod 60 GSK# [002] 60 ENDEAVOR IV 60 Phase #/#a clinical 60 PROVENGE ® 60 relapsed multiple myeloma 60 REG2 60 RRMS patients 60 SCH # 60 refractory chronic lymphocytic 60 cangrelor 60 telomerase inhibitor drug 60 Reverset 60 olaparib 60 Omacetaxine 60 masked placebo controlled 60 desvenlafaxine succinate 60 orally administered inhibitor 60 EOquin 60 pharmacodynamic profile 60 perifosine 60 PrevOnco ™ 60 MDV# 60 indibulin 60 ARIKACE 60 volociximab 60 Phase 60 Pivotal Phase 60 Iloperidone 60 CRx 60 pharmacodynamic properties 60 Kamada AAT 60 subcutaneously administered 60 anticancer compound 60 nitazoxanide 60 prospective multicenter 60 HCV NS5B polymerase 60 oxymorphone ER 60 SABCS 60 bazedoxifene conjugated estrogens 60 SPIRIT IV 60 afatinib 60 JZP 60 CAPACITY trials 60 preclinical studies 60 Parkinson disease levodopa induced 60 class mGluR5 inhibitor 60 INSPIRE Trial Phase III 60 Symadex 60 Thiarabine 60 IND submission 60 GV# [001] 60 Phase III Clinical Trial 60 KNS # 60 ixabepilone 60 Lodotra TM 60 rhIGF-I/rhIGFBP-3 60 ADAGIO study 60 motesanib 60 Novolimus 60 PEARL SC 60 pharmacokinetic pharmacodynamic 60 FOLFOX6 chemotherapy regimen 60 unblind 60 IMC A# 60 preclinical 60 BR.# 60 opioid induced bowel dysfunction 60 Preclinical studies 60 Gabapentin GR 60 RGB # 60 evaluating mipomersen 60 Nexavar sorafenib 60 ganaxolone 60 candidates Dyloject TM 60 regorafenib 60 IPL# 60 Vicriviroc 60 antibody MAb 60 Ketotransdel 60 Serdaxin ® 60 cilengitide 60 MYDICAR ® 60 Allovectin 7 ® 60 novel histone deacetylase 60 maximally tolerated dose 60 intranasal formulation 60 ASSERT trial 60 ozarelix 60 HuMax CD# 60 isavuconazole 60 PROSTVAC VF 60 bendamustine 60 HspE7 60 MGd 60 ofatumumab 60 apremilast 60 CCR5 mAb 60 RoACTEMRA 60 corticosteroid dexamethasone 60 evaluating Actimmune 60 APPRAISE 60 GEM OS2 60 initiated Phase 1b 60 rALLy trial 60 II Clinical Trial 60 GRNVAC1 60 ZYBRESTAT fosbretabulin 60 cetuximab Erbitux 60 CCX# B 60 mipomersen 60 HQK 60 ANG# 60 CoFactor 60 long acting muscarinic 60 cancer neuroendocrine tumor 60 radezolid 60 aleglitazar 60 MEND CABG II 60 NXL# 60 ELND# 60 elagolix 60 hypoxia activated prodrug 60 apricitabine ATC 60 Gastrointestinal Cancers Symposium 60 Phase III metastatic melanoma 60 BiTE antibody MT# 60 XL# [003] 60 microplasmin 60 octreotide implant 60 active comparator 60 Achieves Primary Endpoint 60 docetaxel Taxotere R 60 leading oral taxane 60 REVIVE Diabetes 60 REG1 Anticoagulation System 60 randomized double 60 ALN VSP Phase 60 miconazole Lauriad ® 60 randomized discontinuation trial 60 NSABP B 60 AIR CF2 60 teduglutide 60 Cethrin R 60 Pivotal Trial 60 Æterna Zentaris 60 tremelimumab 60 Zerenex 60 TAXUS ATLAS 60 mg/m2 cohort 60 Dextofisopam 60 ICA # 60 Fodosine 60 initiate Phase 60 Dacogen decitabine 60 lixisenatide 60 ulimorelin 60 CDK inhibitor 60 LymphoStat B 60 LibiGel testosterone gel 59 ADX# 59 BOLDER II 59 NASDAQ BPAX 59 ATL/TV# 59 preclinically 59 aflibercept 59 refractory CLL 59 Amoxicillin PULSYS Phase III 59 HCD# [002] 59 Lupuzor 59 glucokinase activator 59 farletuzumab 59 investigational compound 59 Dalbavancin 59 CLIRS trial 59 sulodexide 59 MIVI III 59 EDEMA3 59 proteasome inhibitor 59 pharmacodynamic effects 59 Phase III VISTA 59 zanolimumab 59 ZACTIMA 59 daclizumab 59 AZX# 59 VA# [002] 59 PRTX 59 evaluating Xcytrin 59 candidate XP# 59 Enzastaurin 59 SAR# [004] 59 pan HDAC inhibitor 59 Clonicel 59 LAS# [002] 59 NEVO ™ 59 Proxinium TM 59 ACCEDE 59 Pafuramidine 59 CA9 SCAN 59 #I TM# 59 custirsen 59 azilsartan medoxomil 59 Phase IIB clinical 59 dexpramipexole 59 StemEx 59 labial herpes 59 evaluating REVLIMID 59 recurrent glioblastoma multiforme 59 Cleviprex TM clevidipine 59 Hyphanox 59 ONCONASE R 59 randomized controlled clinical 59 depsipeptide 59 rindopepimut 59 Teriflunomide 59 CytoFabTM 59 vemurafenib 59 Onconase 59 nab paclitaxel 59 somatostatin analog 59 Ambrisentan 59 Omigard 59 AVE# 59 TG# [001] 59 MIRCERA 59 Tasimelteon 59 Hedgehog antagonist 59 Kahalalide F 59 Augment Injectable 59 dacetuzumab 59 acyclovir Lauriad ® 59 DSMB recommended 59 refractory gout 59 picoplatin 59 prospective randomized controlled 59 PEG IFN 59 RezularTM 59 OMP #M# 59 relapsed myeloma 59 vicriviroc 59 Asentar 59 Dyloject TM 59 talabostat 59 GVAX 59 AMD# [003] 59 Betaferon ® 59 OHR/AVR# 59 nucleotide analogue 59 CYT# potent vascular disrupting 59 NSABP C 59 FIRMAGON R 59 metastatic sarcomas 59 Tesmilifene 59 CB2 selective receptor agonist 59 Omnitarg 59 FORTIS M trial 59 methylnaltrexone 59 OPT CHF 59 immunotherapeutic vaccine 59 investigational hepatitis C 59 Triolex 59 liposome injection 59 Phase 2b Clinical Trial 59 NLX P# 59 DU #b 59 clazosentan 59 ritonavir boosted danoprevir 59 BRAF inhibitor 59 tolerability 59 T Pred 59 maturation inhibitor 59 ROCKET AF 59 dalbavancin 59 safinamide 59 randomized multicenter Phase III 59 Altastaph 59 Amplimexon 59 catheter occlusion 59 investigational pan BCR 59 Saforis 59 MYDICAR 59 cariprazine 59 Afatinib 59 randomized blinded 59 pharmacodynamics 59 Huntexil 59 CLL8 59 NASDAQ NYMX 59 Ereska 59 midstage studies 59 PROVENGE sipuleucel T 59 budiodarone 59 ACTEMRA 59 eosinophilic asthma 59 subcutaneous formulation 59 LAF# 59 Radezolid 59 NASDAQ AVNR 59 statistically significant efficacy 59 interferon beta 1b 59 Aryplase 59 Lu AA# 59 Catena ® 59 phase III ACCLAIM 59 PRE SURGE 59 MAXY alpha 59 evaluating RDEA# 59 HER2 positive metastatic breast 59 sorafenib tablets 59 APEX AMI trial 59 delafloxacin 59 HCV protease inhibitor 59 pazopanib 59 PEGylated interferon 59 Phase 2a proof 59 ZOLINZA 59 docetaxel chemotherapy 59 palifosfamide 59 MVA MUC1 IL2 59 placebo controlled clinical trials 59 registrational studies 59 TRIOLEX 59 PS# DARA 59 GEM OS1 59 Cimzia TM 59 Inhalation Solution 59 Efficacy Results 59 midstage clinical trial 59 Proellex TM 59 biliary tract cancer 59 Prodarsan ® 59 ofatumumab HuMax CD# 59 oral methylnaltrexone 59 blinded randomized 59 ASCO abstract 59 Hsp# inhibitor 59 liprotamase 59 BiTE R 59 Dual Opioid 59 novel VDA molecule 59 evaluating satraplatin 59 multicenter prospective 59 Nasdaq DVAX 59 Harry Palmin President 59 favorable pharmacokinetic profile 59 intravenous dosing 59 MOZOBIL 59 rALLy 59 systemic anaplastic large 59 TRANSFORMS 59 AACR NCI EORTC 59 #mg BID [001] 59 PROTECT AF 59 Vascular Disrupting Agent 59 aplindore 59 GAP #B# 59 NASDAQ ARRY 59 ENMD # 59 Oral NKTR 59 peginesatide 59 investigational oral hepatitis C 59 RG# [001] 59 PRECISE trial 59 unblinded 59 ExTRACT TIMI 59 novel oral anticoagulant 59 omecamtiv mecarbil 59 severe hypercholesterolemia 59 #th Annual Interscience 59 basal bolus regimen 59 Solulin 59 Akt inhibitor 59 Rezular 59 investigational oral 59 sodium thiosulfate STS 59 ACOMPLIA R 59 adecatumumab 59 Nasdaq OPTR 59 Reolysin 59 PCK# 59 ARIKACE ™ 59 Panzem NCD 59 Curaxin CBLC# 59 abiraterone acetate 59 mitogen activated ERK kinase 59 Ixempra 59 leukemia AML 59 AZILECT ® 59 ancrod 59 ONGLYZA ™ 59 telaprevir dosing 59 orBec 59 GSK# [001] 59 standard chemotherapy regimen 59 randomized multicentre 59 RLY# 59 Elocalcitol 59 initiate Phase IIa 59 tiapamil 59 Exelixis compounds

Back to home page